Bloomwell Group
Bloomwell Group is a Frankfurt-based German telemedicine company founded in 2020 that operates a proprietary digital prescription platform connecting patients seeking medical cannabis with a network of 60 doctors and 271 licensed pharmacies, serving over 100,000 patients as of March 2026.
- Company typePrivate
- Founded2020
- HeadquartersFrankfurt, Germany
- Headcount101–250
- GTM typeB2C
- OfferingSoftware
What Bloomwell Group does
Bloomwell Group GmbH is a Frankfurt-based telemedicine company founded in September 2020 that operates a proprietary digital prescription platform connecting patients with a network of doctors for medical cannabis prescriptions. The platform uses proprietary software to transmit electronic prescriptions directly to licensed pharmacies for fulfillment and home delivery, addressing a structural geographic gap in Germany where nearly half of medical cannabis patients live more than 10 kilometers from one of only 271 specialized pharmacies nationwide. The company scaled from 200 monthly patients and four doctors in its initial months to over 100,000 patients and 60 doctors by March 2026, catalyzed by Germany's Cannabis Act (Cannabisgesetz) implemented in April 2024.
The business generates revenue through telehealth consultation and prescription services with usage-based pricing tied to prescription volume and product pricing. Average medical cannabis flower prices on the platform fell from €8.64 per gram in late 2024 to approximately €4.52 per gram by March 2026 as supplier competition intensified post-legalization, compressing unit economics but expanding volume. The company is positioned as a holding entity for European medical and prospective recreational cannabis businesses, with capital raised to prepare for anticipated adult-use legalization in Germany.
Bloomwell has raised over $10 million in disclosed funding across a $10 million seed round in October 2021 led by Measure 8 Venture Partners (reported as the highest known seed round in the EU cannabis sector) and a multi-million Euro round in February 2023 led by Artemis Growth Partners, with participation from Measure 8, a German family office, and actor Moritz Bleibtreu. CEO Dr. Julian Wichmann leads the company, which operates with a 101-250 employee base and competes in a German medical cannabis market that reached approximately $997 million in late 2025, a 155% year-over-year increase.
Bloomwell Group firmographics
Firmographics- Name
- Bloomwell Group
- Legal name
- Bloomwell Group GmbH
- Website
- https://bloomwell.eu
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Bloomwell Group is a Frankfurt-based German telemedicine company founded in 2020 that operates a proprietary digital prescription platform connecting patients seeking medical cannabis with a network of 60 doctors and 271 licensed pharmacies, serving over 100,000 patients as of March 2026.
- Ownership category
- akta.pro rank
Bloomwell Group industry classification
Industry- Product category
- Medical Cannabis Telemedicine
- NAICS
- Offices of Physicians (except Mental Health Specialists) (621111), Offices of Physicians (62111)
- SIC
- Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000)
- akta.pro primary industry
- Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail) (CRANAFAG)
- akta.pro secondary industries
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI), On-Demand Cannabis Delivery (Courier-to-Consumer) (CRANAGAA)
Keywords
Where Bloomwell Group is headquartered
LocationHeadquarters
- HQ city
- Frankfurt
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Bloomwell Group business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Telehealth Consultation and Prescription Services: Bloomwell generates revenue by connecting patients with doctors for medical cannabis prescriptions through its telehealth platform, operating during a period when cannabis was classified as a narcotic and continuing post-legalization.
- Cannabis Product Fulfillment: The company facilitates prescription fulfillment through licensed pharmacies, with medical cannabis flower prices on its platform dropping from €8.64 to €5.95 per gram and further to €4.52 per gram by March 2026, suggesting revenue tied to prescription volume and product pricing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Medical cannabis prescription via telemedicine |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels3 records
Bloomwell Group product offering
Product offeringCore offering
Bloomwell operates a proprietary telehealth platform that connects patients seeking medical cannabis with a network of 60 doctors for virtual consultations and prescriptions. Electronic prescriptions are sent directly to licensed German pharmacies for fulfillment and home delivery. The platform serves over 100,000 patients and is positioned to scale with anticipated adult-use cannabis legalization in Germany.
Product overview
Bloomwell operates a unified telehealth platform that serves as the primary product offering. The platform connects patients with doctors who prescribe medical cannabis, utilizing proprietary digital prescription technology to send electronic prescriptions directly to licensed pharmacies. The company has scaled from its initial launch to over 100,000 patients and a network of 60 doctors, providing both telemedicine consultations and home delivery services for medical cannabis.
Differentiator
Problem solved
Functional benefit
Products and services
- Bloomwell Telehealth Platform A proprietary telemedicine platform connecting patients seeking medical cannabis prescriptions with a network of 60 licensed doctors. The platform facilitates virtual consultations and uses proprietary digital prescription software to send electronic prescriptions directly to licensed pharmacies for fulfillment and home delivery, serving over 100,000 patients in Germany.
Companies that use Bloomwell Group
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Bloomwell Group technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Bloomwell Group partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Licensed PharmaciescoreBloomwell's telemedicine platform connects patients with a network of licensed pharmacies for prescription fulfillment. The company uses proprietary software to send electronic prescriptions directly to pharmacies, which dispense medical cannabis to patients. Germany has only 271 specialized pharmacies nationwide.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Bloomwell Group competitors and assessment
Company assessmentBroad incumbents
- Canopy Growth Corporation: Large multi-jurisdictional cannabis operator with European medical cannabis operations, including Germany; comparable medical cannabis product distribution though broader portfolio focus.
- Aurora Cannabis: Global medical cannabis producer and distributor with European operations including German market presence; comparable medical cannabis supply chain but broader portfolio.
- Tilray Brands: Global cannabis operator with significant German medical cannabis distribution; comparable end-to-end medical cannabis capabilities but broader international portfolio and larger scale.
Direct peers
- Cantourage: Frankfurt-listed German medical cannabis platform facilitating prescriptions and supply chains between cultivators, doctors and pharmacies; directly comparable telemedicine-style prescription fulfillment model in the German market.
- Sanity Group: Berlin-based cannabis company spanning medical and consumer-facing cannabis brands in Germany; comparable medical cannabis distribution, pharmacy partnerships, and German regulatory positioning.
- Cansativa: German medical cannabis distribution and B2B platform bridging producers and pharmacies; comparable digital intermediary model serving the same German pharmacy network.
Regional players
- Demecan: German cannabis cultivator and distributor of medical cannabis, working with German pharmacies and patients; directly comparable medical cannabis supply chain participation in the same geography.
Emerging players
- Nuri (formerly Cansativa/Leafly.de): German cannabis-focused e-commerce/discovery platform serving German cannabis patients; comparable DTC patient acquisition approach for medical cannabis products.
- Dr. Ansgar Wesseling / Medical Cannabis Clinics EU: Grünhorn is a German medical cannabis pharmacy and platform; comparable patient-facing prescription fulfillment and DTC delivery infrastructure serving German cannabis patients.
Others
- Zelira Therapeutics / Levin Health: European/Australian-aligned medical cannabis operators exploring telehealth models; thematically comparable in telemedicine + medical cannabis intersection.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Bloomwell Group social profiles
Digital presenceBloomwell Group financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bloomwell Group leadership team
Management profileNumber of profiles
Profiles3 records
Bloomwell Group funding detail
Funding detailFunding overview
Funding rounds2 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bloomwell Group M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bloomwell Group
What does Bloomwell Group do?
Bloomwell operates a proprietary telehealth platform that connects patients seeking medical cannabis with a network of 60 doctors for virtual consultations and prescriptions. Electronic prescriptions are sent directly to licensed German pharmacies for fulfillment and home delivery. The platform serves over 100,000 patients and is positioned to scale with anticipated adult-use cannabis legalization in Germany.
Is Bloomwell Group a public or private company?
Bloomwell Group is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bloomwell Group founded?
Bloomwell Group was founded in 2020. It employs 101 to 250 people.
Where is Bloomwell Group based?
Bloomwell Group is headquartered in Frankfurt, Germany, in the Europe region.
How does Bloomwell Group make money?
Two revenue lines are on record. Telehealth Consultation and Prescription Services are the primary driver. The others are cannabis Product Fulfillment.
Who are Bloomwell Group's main competitors?
Broad incumbents on record are Canopy Growth Corporation, Aurora Cannabis and Tilray Brands. Direct peers are Cantourage, Sanity Group and Cansativa. Demecan is listed as a regional player. Emerging players are Nuri (formerly Cansativa/Leafly.de) and Dr. Ansgar Wesseling / Medical Cannabis Clinics EU. Zelira Therapeutics / Levin Health is listed as an others.
Does Bloomwell Group have an API?
No public API is recorded for Bloomwell Group.
What industry is Bloomwell Group in?
Bloomwell Group's product category is Medical Cannabis Telemedicine. Its primary akta.pro industry code is CRANAFAG, Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail), with a secondary code of CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services). Its NAICS code is 621111 and its SIC code is 8011.